Drug Royalty Corporation

Drug Royalty Corporation, now known as DRI Capital, is a pioneer in the pharmaceutical royalty finance sector. Established in 1992 and headquartered in Toronto, the company focuses on acquiring royalty interests in high-quality, late-stage or approved pharmaceutical products. By providing upfront capital to academic institutions, hospitals, and biotechnology companies, the firm enables these entities to monetize their future cash flows. The company's historical portfolio has included royalties on significant global brands such as Enbrel, Remicade, and Humira. Following its acquisition and privatization in 2002, the firm has continued to operate as a leading private equity manager in the life sciences space.